Heather Holdiness, APRN
Adult Health · Hot Springs Village, ARNPI 1053744391
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $533 and has fallen 60.5% since, to $211 in 2025.
Across 94 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$194
- AbbVie$136
- Abbott$131
- Novo Nordisk$129
- GSK$127
- Sumitomo Pharma America, Inc.$127
- plus $783 from 16 others
What the payments were for
- Food & beverage$1,60398%
- Education$252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $194 |
| AbbVie | 9 | $136 |
| Abbott | 7 | $131 |
| Novo Nordisk | 8 | $129 |
| GSK | 8 | $127 |
| Sumitomo Pharma America, Inc. | 8 | $127 |
| Otsuka America Pharmaceutical, Inc. | 5 | $125 |
| Sunovion Pharmaceuticals Inc. | 6 | $91 |
| Currax Pharmaceuticals LLC | 5 | $82 |
| Amgen | 4 | $81 |
| Lundbeck LLC | 5 | $76 |
| Lilly USA, LLC | 4 | $56 |
| AstraZeneca | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $34 |
| Eisai Inc. | 1 | $34 |
| Astellas Pharma US Inc | 2 | $33 |
| Novartis | 1 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Corium, LLC | 1 | $15 |
How this compares
$1,628 in reported general payments places this provider in the 70th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $90,772 |
| EliquisApixaban | 28 | $29,936 |
| MyrbetriqMirabegron | 38 | $22,526 |
| FarxigaDapagliflozin Propanediol | 13 | $19,601 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,268 |
| EntrestoSacubitril/Valsartan | 13 | $11,119 |
| GemtesaVibegron | 13 | $6,415 |
| Lagevrio (Eua)Molnupiravir | 23 | $5,113 |
| Pravastatin Sodium | 215 | $2,478 |
| Atorvastatin Calcium | 279 | $2,365 |
| Losartan Potassium | 228 | $2,225 |
| Levothyroxine Sodium | 247 | $2,176 |
| Bupropion XlBupropion Hcl | 78 | $1,906 |
| Famotidine | 86 | $1,566 |
| Diclofenac Sodium | 79 | $1,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $129 | $90,77279 claims |
| PfizerEliquis, Paxlovid | $194 | $31,36542 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $22,52638 claims |
| AstraZenecaFarxiga | $37 | $19,60113 claims |
| GSKAnoro Ellipta | $127 | $12,26827 claims |
| NovartisEntresto | $25 | $11,11913 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $127 | $6,41513 claims |
| AbbVieSynthroid | $136 | $1,50352 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 154 adult health providers in Arkansas.
Other adult health in Hot Springs Village
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Darren CompasBentonville$8K
- Lisa HarveyHot Springs$8K
- Abby MartensSpringdale$7K
- Marie JonesFayetteville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.